Korsana Biosciences, Inc. Common Stock
KRSA
70 hedge funds and large institutions have $105M invested in Korsana Biosciences, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 12 closing their positions.
113% more capital invested
Capital invested by funds: $49.1M → $105M (+$55.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.03% less ownership
Funds ownership: 66.76% → 63.73% (-3%)
5% less funds holding
Funds holding: 74 → 70 (-4)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$36.5K |
| 2 |
D.E. Shaw & Co
New York
|
+$33.1K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$27.8K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$27.1K |
| 5 |
Renaissance Technologies
New York
|
+$17.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$331K |
| 2 |
HKAM
Horizon Kinetics Asset Management
New York
|
-$194K |
| 3 |
AC
AWH Capital
Dallas,
Texas
|
-$163K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$102K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$75K |
KRSA Hedge Fund Activity: Q2 2020 in Review
70 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2020, worth a combined $105M — up 113% from $49.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KRSA and 8 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 18 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $36.5K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $331K sold.
- 70 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2020, down from 74 in Q1 2020.
- Funds reported $105M of Korsana Biosciences, Inc. Common Stock stock for Q2 2020, up 113% quarter-over-quarter.
- 8 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2020 and 12 closed out, a net change of -4 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2020 was Bridgeway Capital Management, an estimated $36.5K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q2 2020 was Sphera Funds Management, an estimated $331K sold.
Based on aggregated 13F filings for Q2 2020.